Company, executives agree to settle allegations, pay US$41 million
Execs falsely inflated firm's revenues to enable acquisition, regulator charges
Previously banned advisor found guilty of six out of 10 counts
Ex-CEO misled investors over regulatory approval for new drugs
Company to appeal denied $213M claim against flagship fund
Releases were misleading, but case against lawyer not proven, panel finds
Normally, major frauds should carry disgorgement orders, Tribunal says
Crypto fraud rising, as scams scale up and adopt AI tools: report
Regulatory action deals with subset of $1.8 million misappropriation
U.S. authorities allege biostatistician traded on cancer drug data